Fundz

AIM ImmunoTech Inc. announces a registered direct offering and private placement, raising approximately $2.4 million. The company plans to use the funds for drug supply, clinical trials, and working capital.

PUBLIC · AIMMay 20, 2026

Amount Raised

$2.4 Million

Round Type

Post-IPO Equity

OcalaBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical

Investors

Ladenburg Thalmann & Co. Inc.

Description

AIM ImmunoTech Inc. has entered into agreements for a registered direct offering of 7,519,351 shares of common stock at $0.325 per share, expected to raise around $2.4 million. The company also plans a concurrent private placement of Series I warrants. Ladenburg Thalmann & Co

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as AIM ImmunoTech that raised within 45 days of this round, from Fundz verified event records.

  • Os Therapies raised $1.6M on June 30, 2026.
  • NewcelX raised $2.9M on July 3, 2026.
  • Decoy Therapeutics raised $3.5M (Post-IPO Equity) on June 29, 2026.
  • Bionyra Pharma raised $165M (Series A) on June 22, 2026.
  • Tempest Therapeutics raised $4.1M on May 29, 2026.
  • IRulya Therapeutics Inc. raised $115M on May 18, 2026.

Who to call at AIM ImmunoTech, and when

A new round usually means AIM ImmunoTech is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day AIM ImmunoTech raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AIM ImmunoTech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AIM ImmunoTech. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AIM ImmunoTech

Location

Ocala, Florida, United States

About

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AIM ImmunoTech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

5 contacts
Verified contactsDavid C., Member Board of Directors hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for AIM ImmunoTech's next move

See what Strategic adds

AIM ImmunoTech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.